Overview
Paloma Health provides autism assessment services for children in England by partnering with the NHS to deliver diagnostic evaluations. It conducts autism assessments as part of NHS pathways, coordinating with clinicians to determine diagnoses and connect families with recommended supports, with revenue from NHS service agreements. The company differentiates itself as an NHS-aligned specialist provider focused on pediatric autism diagnostics, operating within the public healthcare system rather than as a generic private clinic. Its goal is to improve outcomes for children with autism and their families by delivering accurate diagnoses and timely access to appropriate supports within the public health framework.
Work here?Claim your company
Simplify's take
What believers are saying
- Paloma updated wait times on November 3, 2026, showing active service delivery.
- The company expanded into joint ADHD-autism assessments, widening addressable NHS demand.
- A £2m pre-seed round from Triple Point Ventures funds rollout and hiring.
What critics are saying
- Ten ICBs paused Paloma referrals until April 2027, cutting revenue from major NHS buyers.
- West Yorkshire imposed a 104-week minimum wait, signaling local resistance to Paloma's model.
- If ICB funding caps spread, Paloma loses NHS volume and the business becomes nonviable.
What makes Paloma Health unique
- NHS-commissioned autism assessments under Right to Choose, updated October 2026.
- Remote autism appointments are typically four weeks, far faster than local NHS queues.
- Paloma combines autism and ADHD pathways into one referral, one report, one waitlist.
Help us improve and share your feedback! Did you find this helpful?